Skip to main content
Premium Trial:

Request an Annual Quote

Australia's Proteomics International Laboratories Launches A$6M IPO

NEW YORK(GenomeWeb) – Australian proteomics firm Proteomics International Laboratories today said it plans to offer up to A$6 million (US$5.2 million) of its shares in an initial public offering on the Australian Stock Exchange.

The firm said in a prospectus that it seeks to raise between A$4 million and A$6 million through an offering of up to 30 million shares of its stock at A$.20 per share. The proceeds will be used to drive growth in each of its three business units: analytical services, diagnostics, and therapeutics.

Founded in 2001, Perth-based PIL offers proteomics services including contract research, analytical testing, and consulting. The company also has a biomarker development program focused on diabetic kidney disease and Alzheimer's disease, as well as a therapeutics program focused on peptide drug discovery from venoms with a focus on painkillers and antibiotics.

Since its founding, PIL has generated gross revenues of A$7.5 million.

The company opened the stock offering on November 3 and plans to close it on November 28 in anticipation of a December 16 listing on the ASX.

The Scan

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Whale Decline Analysis

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.